РОЛЬ СТРЕСС-ИНДУЦИРОВАННЫХ МОЛЕКУЛ MICA/B В ПРОТИВООПУХОЛЕВОМ ИММУННОМ ОТВЕТЕ
Аннотация
Об авторе
Е. В. Абакушина
ФГБУ Медицинский радиологический научный центр Минздрава России, Москва
Россия
Россия
Список литературы
1. Cell stress proteins. Ed. by S.K. Calderwood. Springer. V7. 2007.
2. Groh V, Rhinehart R, Secrist H, et al. Broad tumorassociated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879-6884.
3. Bahram S. MIC genes: from genetics to biology. Adv Immunol 2000; 76: 1–60.
4. Bauer S, Groh V, Wu J. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 30, 285, 5428, 727-729.
5. Whiteside TL, Herberman RB. The role of natural killer cells in human disease. Clin Immunol Immunopathol 1989; 53: 1-23.
6. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science 2004; 306: 1517–1519.
7. Steinle A, Li P, Morris DL, et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 2001; 53: 279-287.
8. Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005; 105: 251–258.
9. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102: 1389–1396.
10. Holdenrieder S., Stieber P., Peterfi A., et al. Soluble MICA in malignant diseases. Int J Cancer 2006, 1, 118(3): 684-7.
11. Zwirner N, Fuertes M, Girart M-V, et al. Cytokinedriven regulation of NK cell function in tumor immunity: role of the MICA-NKG2D system. Cytokine and growth factor reviews 2007, 18:159-170.
12. Kenneth F. May. Isolation of human anti-MICA antibody from cancer patient responding to immunotherapies. June 2012, ASCO Annual meeting.
Рецензия
Для цитирования:
Абакушина Е.В. РОЛЬ СТРЕСС-ИНДУЦИРОВАННЫХ МОЛЕКУЛ MICA/B В ПРОТИВООПУХОЛЕВОМ ИММУННОМ ОТВЕТЕ. Злокачественные опухоли. 2012;2(2):102-104. https://doi.org/10.18027/2224-5057-2012-2-102-104
Просмотров: 497
Послать статью по эл. почте 